Tuesday, 16 Jul 2019

You are here

Could Measuring Drug Levels with TNF Treatment Hurt Your Patients?

Our colleagues in gastroenterology measure drug levels with certain biologics used in inflammatory bowel disease in order to increase the dose for optimal benefit if the patient has a low trough level (i.e. targeting drug level).

There have been GI trials with T2T with drug levels but they are not always suggesting that the strategy is superior to usual care. Also, this is really not a common practice in rheumatology.

An interesting study (OP0229) linked patients from the BSRBR (British Biologic Register) on a TNFi who also had serum samples taken to calculate drug levels (N=703). Two thirds had high drugs levels (which is very surprising to me as I suspected it would be far less than that due to non-adherence, spacing treatment when doing well, etc).

Those with a high level had more infections (Hazard Ratio 1.51; 95% CI 1.14-2.01) but the serious infections were not statistically more (HR 1.17; 95% CI 0.58-2.30).

Perhaps drug levels could help us identify if a patient could take less TNFi treatment and possibly reduce the number of infections. However, the study used serum samples collected for other reasons and then for this study performed drug levels so I wonder if many of the levels were not trough levels.

This study did not measure efficacy between the group nor durability of the groups so I can’t comment on any potential differences between the groups with respect to disease state and drug retention. It is something though to think about if we are to personalize medicine – get what you need and not more and not less. 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

EHR-Related Adverse Events Usually Involve Medications

Concerns about the unintended risks inherent in electronic health records (EHR) by analysis of EHR–related harms identified from large database of malpractice suits and claims; they found that EHR related adverse events exist, and may be associated with an severe harms and uncommonly, death.

Methotrexate Use Not Linked to Interstitial Lung Disease in RA

People with rheumatoid arthritis have a significant risk of developing interstitial lung disease (RA-ILD), yet there is often a question as to whether methotrexate (MTX) exposure can cause or worsen ILD.  A controlled cohort study suggests that MTX use is not associated with an increased risk of RA-ILD and instead, there is evidence suggesting MTX use may delay the onset of ILD.

FDA Adds Boxed Warning to Sleep Drugs

The Food and Drug Administration (FDA) added a Boxed Warning to several sleep medications (e.g., eszopiclone, zaleplon, and zolpidem), warning rare but serious injuries may occur as a result of abnormal sleep behaviors (sleepwalking, sleep driving, and engaging in other activities while not fully awake) when taking sleep medications. These complex sleep behaviors have also resulted in deaths.

Update on Vaccines in Autoimmune Patients

Although both the disease and the treatment for it in rheumatology patients may work at cross-purposes with immunizations, only a very few vaccines are absolutely contraindicated in this population, an infectious disease specialist told rheumatologists here.

RheumNowLive On Demand: Infection Prevention and Management with Newer Agents - Jack Cush, MD

A clip from RheumNow Live On Demand. You can access the full library of content from the meeting.